Search for a trial

OPEN-LABEL, MULTI-CENTER, SINGLE-ARM STUDY FOR THE SAFETY AND EFFICACY OF
POMALIDOMIDE (CC-4047) MONOTHERAPY FOR SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA. A COMPANION STUDY FOR CLINICAL TRIALCC-4047-MM-003.

The primary objective is:To evaluate the efficacy of pomalidomide (CC-4047) monotherapy in subjects with refractory orrelapsed and refractory multiple myeloma who discontinued treatment after being treated withdexamethasone alone (Treatment Arm B)…

T and NK cell mediated immunotherapy in Ewing's sarcoma (P03.040 amended version of December 2006)

We hypothesize that NK and/or T cell-mediated immunotherapy may represent a novel therapeutic option for patients with refractory and/or metastatic ES. Therefore, we will study molecular mechanisms that determine the susceptibility of ES to T and NK…

T and NK cell mediated immunotherapy in osteosarcoma; a preclinical feasibility study

We hypothesize that NK and/or T cell-mediated immunotherapy may represent a novel therapeutic option for patients with refractory and/or metastatic OS. Therefore, we will study molecular mechanisms that determine the susceptibility of osteosarcomas…

A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first-line or later-line treatment in advanced chordoma.

Primary objectives- To evaluate the treatment efficacy by progression free survival (PFS) according to RECIST 1.1. - Quality of life assessmentSecondary objectives- To evaluate the treatment efficacy by growth modulation index- To evaluate the…

Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel

This study has been transitioned to CTIS with ID 2023-505530-10-00 check the CTIS register for the current data. The purpose of this long-term follow-up study is to monitor the health status of patients who were previously enrolled in cilta-cel…

Reduced dose-density of denosumab for maintenance therapy of unresectable giant cell tumor of bone: a multicenter phase II study "REDUCE"

The primary objective of the trial is to evaluate the risk versus benefit of denosumab in maintenance setting in patients requiring long-use (>1 year) of denosumab. For that purpose, the treatment schedule with reduced dose density (120mg SC…

PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE® ) IN
COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE AND/OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN
PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID
TUMORS

Primary: To compare the efficacy of palbociclib in combination with TMZ and IRN vs TMZ and IRN chemotherapy alone in the treatment of children, adolescents, and young adults with recurrent or refractory EWS.Secundary: To further compare the efficacy…

A phase 2, single arm, multi center trial evaluating the efficacy of the combination of sirolimus and cyclophosphamide in metastatic or unresectable myxoid liposarcoma and chondrosarcoma.

- To evaluate the treatment efficiency by time to progression according to RECIST 1.1